Inotuzumab Ozogamicin
Precursor B-Cell Acute Lymphoblastic Leukemia
Explore 24 assets in Precursor B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Zhejiang University
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06554626CT.gov Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL | — | Recruiting | — | — | — |
NCT03249870CT.gov Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Inotuzumab Ozogamicin (this asset) | First Affiliated Hospital of Zhejiang University | P2 | B · 57 |
| Blinatumomab | Amgen | P3 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2/3 | BB |
| Cyclophosphamide | Princess Maxima Center for Pediatric Oncology | P2/3 | BB |
| Cytarabine | Princess Maxima Center for Pediatric Oncology | P2 | B |
| Olverembatinib | First Affiliated Hospital of Zhejiang University | P2 | B |
| Pegaspargase | First Affiliated Hospital of Zhejiang University | P2 | B |
| Methotrexate | First Affiliated Hospital of Zhejiang University | P2 | B |
| Dexasone | Princess Maxima Center for Pediatric Oncology | P2 | B |
+19 more in the Precursor B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for Inotuzumab Ozogamicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BB · 69 |
| B-Cell Acute Lymphoblastic Leukemia | — | P4 | BB · 67 |
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Inotuzumab Ozogamicin in Precursor B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/inotuzumab-ozogamicin-precursor-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →